Not Yet RecruitingNot Applicable

Assessment of Laryngopharyngeal Sensation: Cancer Survivor Cohort

United States40 participantsStarted 2025-10-01

Plain-language summary

A previous study completed in 2022 (NCT05158179) was conducted using cohorts of healthy controls, and adults with general laryngopharyngeal disorders. This study will expand on the previous research to include a separate cohort of adults being seen in clinic for an existing laryngopharyngeal disorder resulting from previous radiation or other cancer treatments.

Who can participate

Age range18 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age \<=18 years.
✓. Individuals without a laryngopharyngeal disorder (health controls) or with a laryngopharyngeal disorder. Laryngopharyngeal disorder includes but is not limited to: presbylarynx, aspiration; spasmodic dysphonia; globus pharynges; vocal fold paralysis; iatrogenic injury to the larynx; muscle tension dysphonia; neurogenic dysphagia; laryngeal sensory neuropathy; and laryngopharyngeal disorders resulting from prior radiation therapy in individuals with a history of head and neck cancer who have completed radiation therapy as primary or adjuvant cancer treatment
✓. Ability and willingness to comply with study procedures.
✓. Ability to understand a written informed consent document, and the willingness to sign it.

Exclusion criteria

✕. Non-English speaking.
✕. Laryngopharyngeal structures are not accessible on exam.
✕. Known contraindication to any study-related procedure, or history of being unable to tolerate laryngoscopy.
✕. Vocal fold immobility or severe hypomobility on adduction.
✕. For head and neck cancer survivors only: Currently undergoing radiation therapy for head and neck cancer (i.e., primary/adjuvant radiation therapy treatment plan is not yet completed).

What they're measuring

Percentage of participants with triggered/positive laryngeal adduction response (LAR)

Timeframe: 1 day

Median scores on the Penetration-Aspiration Scale (PAS)

Timeframe: 1 day

Trial details

NCT IDNCT06078527

SponsorUniversity of California, San Francisco

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-01-31

Contact for this trial

Yue Ma, MD

877-827-3222 cancertrials@ucsf.edu

View on ClinicalTrials.gov More Presbylarynx trials